Market research
EVFM Evofem Biosciences Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 928K
- P/E ratio
- Not available
- Analyst target
- 225
- Dividend yield
- Not available
- Beta
- -1.34
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US30048L2034
- Market cap
- 928K
- P/E ratio
- Not available
- Analyst target
- 225
- Dividend yield
- Not available
- Beta
- -1.34
About
About Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EVFM discussion.
5 years, 4 months ago
Evofem Biosciences, Inc is currently in a long term downtrend where the price is trading 55.6% below its 200 day moving average.
From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 281.6.
Evofem Biosciences, Inc's total revenue rose by inf% to $168K since the same quarter in the previous year.
Its net income has dropped by 219.2% to $-41M since the same quarter in the previous year.
Finally, its free cash flow fell by 198.1% to $-40M since the same quarter in the previous year.
Based on the above factors, Evofem Biosciences, Inc gets an overall score of 2/5.